The main purpose of the Screening Group is to provide hit identification and hit-to-lead optimization contract services to the biotech and pharmaceutical industry. We are also open to discuss shared-risk exploratory hit finding projects with the industry or academic partners, including the discovery and optimization of various assays and pharmacological tool compounds for new or poorly validated targets.

HTS Laboratory at Bienta is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities and the capacity to run both biochemical and cell-based assays in 384-well plate format.

Assay read-out platforms:

  • UV-VIS absorbance
  • luminescence
  • fluorescence intensity
  • fluorescence polarization
  • time-resolved fluorescence/energy transfer (FRET, TR-FRET, HTRF, DELFIA, LANCE)
  • cellular calcium mobilization (FLIPR)
  • ELISA
  • AlphaScreen
  • enzyme/reporter assays
  • cell viability assays

Our Protein Thermal Shift Screening Platform (or Differential Scanning Fluorimetry) includes ViiA 7 System (Applied Biosystems) and two FluoDia T70 (Photal) readers.

Our strategy of “smart screening” is based on the extensive use of our chemoinformatics and molecular modelling resources and iterative access to Enamine’s on-site compound repository of close to 2,000,000 compounds after each round of experimental screening of in silico generated compound sets. Optimization of the obtained hits/leads can be facilitated by on-site access to Enamine’s high-throughput parallel chemistry lab. This unmatched combination of the powerful resources sets us apart from any competition.